AN2 Therapeutics Inc (ANTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.89-1.01%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ANTX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 26.6 | 24.8 | 40.5 | 54.9 | 28.5 | 16.2 | — |
| Operating Income | (38.8) | (38.1) | (56.8) | (69.6) | (42.3) | (21.6) | — |
| Earnings from Continuing Operations | |||||||
| Interest & Investment Income | 2.5 | 2.9 | 5.5 | 4.9 | — | — | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | — |
| Net Income | |||||||
| Net Income | (36.3) | (35.2) | (51.3) | (64.7) | (41.0) | (21.5) | — |
| Per Share | |||||||
| Basic EPS | (0.81) | (1.16) | (1.72) | (2.74) | (2.79) | (10.64) | — |
| Diluted EPS | (0.81) | (1.16) | (1.72) | (2.74) | (2.79) | (10.64) | — |
| Basic Weighted Avg Shares | 44.8 | 30.2 | 29.8 | 23.6 | 15.3 | 2.6 | — |
| Diluted Weighted Avg Shares | 44.8 | 30.2 | 29.8 | 23.6 | 15.3 | 2.6 | — |
| Supplemental | |||||||
| EBIT | (38.8) | (38.1) | (56.8) | (69.6) | (42.3) | (21.6) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.